

1 **Anemia during pregnancy and adverse maternal**  
2 **outcomes in Georgia – a birth registry-based cohort**  
3 **study**

4 *Anemia in pregnancy and maternal outcomes*

5 Authors: Natia Skhvitaridze<sup>1,2,3\*</sup>, Amiran Gamkrelidze<sup>3</sup>, Tinatin Manjavidze<sup>1,2,3</sup>, Tormod Brenn<sup>1</sup>, Erik  
6 Anda<sup>1</sup>, Charlotta Rylander<sup>1</sup>

7 **Affiliations**

8 <sup>1</sup>Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway

9 <sup>2</sup>National Center for Disease Control and Public Health, Tbilisi, Georgia

10 <sup>3</sup>The University of Georgia, Tbilisi, Georgia

11

12 \*Corresponding author

13 Email: [natia.skhvitaridze@uit.no](mailto:natia.skhvitaridze@uit.no) (NS)

14

15

16

17

## 18 **Abstract**

19 **Background** Anemia in pregnancy is an important public health challenge; however, it has  
20 not been thoroughly studied in Georgia. We assessed the prevalence of anemia during pregnancy  
21 across Georgia and the association between anemia in the third trimester of pregnancy and  
22 adverse maternal outcomes.

23 **Methods** We used data from the Georgian Birth Registry and included pregnant women who  
24 delivered between January 1, 2019, and August 31, 2022 (n=158,668). The prevalence of anemia  
25 (hemoglobin (Hb) < 110 g/L) at any time during pregnancy was calculated per region. Women in  
26 the third trimester were classified into three groups, based on their lowest measured Hb value: no  
27 (Hb  $\geq$ 110 g/L, reference group); mild (Hb 100-109 g/L); and moderate to severe anemia (Hb <99  
28 g/L). Adjusted odds ratios (aOR) with 95% confidence intervals (CIs) were calculated for the  
29 associations between anemia status and post-delivery intensive care unit (ICU) admission and  
30 preterm delivery.

31 **Results** The prevalence of anemia occurring at least once during pregnancy was 40.6%, with  
32 large regional differences in anemia prevalence (25.1%–47.0%). Of 105,811 pregnant women with  
33 Hb measurements in the third trimester, 71.0% had no anemia; 20.9%, mild anemia; and 8.1%,  
34 moderate or severe anemia. The odds of post-delivery ICU admission did not increase linearly with  
35 decreasing Hb value (*P* for trend .13), and the relationship was inverse for preterm delivery (*P* for  
36 trend .01).

37 **Conclusions** A considerable proportion of pregnant women in Georgia have anemia during  
38 pregnancy, and the prevalence and quality of reporting differ across regions. Anemia occurring in  
39 the third trimester did not substantially increase the odds of maternal ICU admission or preterm  
40 delivery. To accelerate national progress toward the Sustainable Development Goals and mitigate

It is made available under a [CC-BY 4.0 International license](#) .

- 41 the consequences of anemia, equal countrywide access to high-quality antenatal care programs
- 42 and complete registration of Hb values should be ensured.

## 43 Introduction

44 Anemia in pregnancy, defined as a hemoglobin (Hb) level below 110 g/L [1], is an important public  
45 health challenge, affecting 30-60% of pregnancies globally, and mainly women in the third trimester  
46 [2-4]. Iron deficiency, generally due to a low dietary iron intake, is the most common cause of  
47 anemia. It has been estimated that iron deficiency anemia contributes almost 22% to maternal  
48 deaths worldwide, most occurring in low-income countries [5]. Several systematic reviews and  
49 meta-analyses have reported that anemia in pregnancy significantly increases the risk of preterm  
50 delivery [6-8]. Moreover, increased risk of maternal mortality and other adverse outcomes, such as  
51 severe post-partum hemorrhage, maternal shock, and admission to the post-delivery intensive care  
52 unit (ICU), have also been associated with anemia [9-11]. However, recent studies have reported  
53 both positive and inverse associations between anemia in pregnancy and several adverse maternal  
54 outcomes. This could be due to differences in screening, follow-up approaches, and treatment  
55 regimens, and the contradictory results pose significant challenges for decision- and policymakers  
56 in implementing evidence-based recommendations [2, 12, 13].

57 The diagnosis of anemia is straightforward but the disease is silent, with few physical symptoms,  
58 and it is much more complex to identify the underlying causes of anemia [14]. Many women in low-  
59 and middle-income countries may also have had undiagnosed anemia before the pregnancy [13].  
60 Initiated by the World Health Organization (WHO), the World Health Assembly approved global  
61 targets for maternal, infant, and young child nutrition in 2012 with a commitment to reduce the  
62 prevalence of anemia in women of reproductive age by 50% before 2025 [15]. In 2020, ending  
63 anemia in women aged 15–49 was added to the Sustainable Development Goals indicator 2.2.3  
64 [16]. The deadline for the global targets has been extended to 2030 [17]. Despite this, knowledge  
65 about global progress toward the anemia target is scarce, and global comparisons are challenged  
66 by differences in the reporting of anemia prevalence across countries [18]. Thus, the disease  
67 remains underdiagnosed and understudied [19].

68 Georgia is an upper-middle-income country in the Caucasus with a population of 3.7 million [20].  
69 Reducing maternal anemia and improving reproductive healthcare are national priorities in Georgia.  
70 However, little is known about the prevalence of anemia in the country and its impact on maternal  
71 morbidity. The most recent study on this subject is the Georgian National Nutrition Survey  
72 conducted in 2009, in which 25.6% of pregnant women had anemia [21]. This study aimed to  
73 provide information about the national and regional prevalence of anemia in pregnant women in  
74 Georgia and to evaluate the associations between anemia in the third trimester and maternal  
75 transfer to the post-delivery ICU and preterm delivery.

## 76 **Materials and methods**

### 77 **The Georgian Birth Registry**

78 Following World Health Organization recommendations, eight antenatal care (ANC) visits are free  
79 of charge for Georgian citizens [22]. Most pregnant women in Georgia attend at least one ANC visit  
80 (95.8% in 2021) and deliver in a health facility (99.8% in 2021) [23]. The Georgian Birth Registry  
81 (GBR) contains countrywide information of all medical facility-based deliveries and ANC visits [24,  
82 25]. The coverage of newborns registered in the GBR was 99.8% in 2021 [26]. Registering  
83 information in the GBR is mandatory for the involved healthcare facilities. The GBR includes many  
84 variables, including demographic characteristics, disease history, and information about the current  
85 pregnancy up to post-delivery hospital discharge [26]. The GBR also includes Hb levels registered  
86 during ANC visits. According to national guidelines, the first ANC visit, recommended before  
87 gestational age (GA) week 13, should include a full blood count, including Hb measurement. Hb  
88 levels should be measured again at the third ANC visit at GA week 26, the fourth ANC visit at GA  
89 week 30, and the sixth ANC visit at GA week 36 [27]. The study data were accessed for research  
90 purposes on July 12, 2023.

91

## 92 **Study sample**

93 We initially included the data of all women registered in the GBR who gave birth between January  
94 1, 2019, and August 31, 2022, who were at least at GA 22 weeks (n=166,043). We excluded  
95 women who did not attend ANC during their pregnancy (n=7,375), resulting in an analytical sample  
96 of 158, 668 women. Of these, 28,709 women attended ANC, but had no or no reliable Hb measure  
97 registered in the GBR. To calculate the national and regional prevalence of anemia among women  
98 who delivered after week 22, we used the data of all women who had at least one Hb measurement  
99 during the pregnancy (n=129,959). To study the association between anemia severity, post-delivery  
100 ICU admission, and preterm delivery, we included only women with at least one Hb measurement  
101 in the third trimester (GA week 28 and onwards; n=105,811 women). For the third trimester cutoff,  
102 we followed the recommendations of the National Institute for Health and Care Excellence, UK [28]  
103 (Fig. 1).

104 Figure 1. Flow chart of the study sample

105

## 106 **Exposure and covariates**

107 Hb levels  $\leq 40$  g/L or  $\geq 180$  g/L were considered implausible [29] and were recoded as “missing.”  
108 Women were considered to have anemia at any time during pregnancy if their lowest recorded Hb  
109 level was  $< 110$  g/L. We classified pregnant women into anemia severity groups based on their  
110 lowest measured Hb value at any time during pregnancy (total study sample) or during the third  
111 trimester (sub-sample used for the regression analysis): no anemia (Hb  $\geq 110$  g/L, reference group);  
112 mild anemia (Hb 100–109 g/L); moderate (Hb 70–99 g/L) and severe (Hb  $< 70$  g/L) anemia. The  
113 moderate and severe anemia groups were combined in the regression analysis because of the  
114 limited number of women in the severe anemia group. The thresholds for Hb levels were based on  
115 the WHO recommendation for anemia classification [1].

116 Information on sociodemographic characteristics (maternal age, residency, and education), year of  
117 delivery, obstetric history (frequency of ANC, parity, plurality, mode of delivery, and bleeding during  
118 pregnancy), body mass index (BMI) at the first ANC visit before GA week 13, and GA at the lowest  
119 recorded Hb value were extracted from the GBR. Maternal age was defined as the mother's age at  
120 delivery. Residence was categorized as rural, urban, or unknown, and education was classified as  
121 primary, secondary, higher, or unknown. We dichotomized most covariates related to obstetric  
122 history: parity as primiparous or multiparous, plurality as singleton or multiple, and bleeding during  
123 pregnancy as yes or no, based on the International Classification of Disease version 10 (ICD10)  
124 code O 20.0 [30]. Number of ANC visits was divided into three groups (<4 visits; 4-8 visits; >8  
125 visits), and the mode of delivery was grouped into two - cesarean section or vaginal delivery. BMI at  
126 the first ANC visit <GA week 13 was divided into five groups according to the WHO classification of  
127 body weight status (<18.5 kg/m<sup>2</sup>, 18.5–24.9 kg/m<sup>2</sup>, 25–30 kg/m<sup>2</sup>, >30 kg/m<sup>2</sup> and missing BMI before  
128 GA week 13) [31].

## 129 **Outcomes**

130 We extracted information on the two main outcomes, post-delivery ICU admission and preterm  
131 delivery from the GBR. Post-delivery ICU admission was defined as any admission to the post-  
132 delivery ICU during or after delivery. Preterm delivery was defined as delivery before GA week 37.

## 133 **Ethics and consent**

134 Regional Committees for Medical and Health Research Ethics in Northern Norway approved the  
135 study protocol (Ref: 577179, 20/02/2023). All data included in this study were extracted from the  
136 GBR and anonymized before the researchers received the data. Registration in the national  
137 registries is mandatory by law, and citizens cannot refuse registration. Consent was not obtained  
138 from the study participants as it is deemed unnecessary according to national regulations [32].

139 The study reporting is in line with the Helsinki declaration and the strengthening the reporting of  
140 observational studies in epidemiology (STROBE) guideline.

## 141 **Statistical analysis**

142 We calculated the period prevalence (2019–2022) of anemia at any time during pregnancy per  
143 region by dividing the number of pregnant women in each region with at least one Hb measurement  
144 of < 110 g/L (anemia cases) by the total number of women in that region with at least one valid Hb  
145 measurement registered in the GBR during the same study period. Descriptive statistics for anemia  
146 testing status are presented as frequencies and percentages for nominal variables and means and  
147 standard deviations for continuous variables.

148 Binary logistic regression assessed the associations between anemia (three exposure groups) in  
149 the third trimester and post-delivery ICU admission and preterm delivery. We estimated crude  
150 associations and associations adjusted for confounding factors. We drew directed acyclic graphs  
151 (DAGs) to identify possible confounding factors between anemia during pregnancy and post-  
152 delivery ICU admission and preterm delivery. The relationships depicted between the variables  
153 included in the DAGs are based on previous literature and the underlying theory (details are  
154 described in Supplementary file 1 and 2). The DAGs assumed that anemia had a causal effect on  
155 the outcomes. Based on the DAGs, the post-delivery ICU admission model was adjusted for age,  
156 BMI, bleeding during pregnancy, cesarean section delivery, and parity, and the preterm delivery  
157 model was adjusted for age, education, BMI, bleeding during pregnancy, and plurality. The results  
158 were presented as crude and adjusted odds ratios (aORs) with 95% confidence intervals (CIs). We  
159 included continuous Hb values in the logistic regression models to test for linear trends and  
160 extracted the *P* value, corresponding to one incremental change in Hb. The significance threshold  
161 was set at .05. All statistical analyses were performed using STATA version 17 (StataCorp, TX,  
162 USA).

## 163 **Results**



164 During the study period, 52,826 pregnant women had anemia (Hb <110 g/L) at least once during  
165 pregnancy, translating into a prevalence of 40.6%. Of these, 28.3%, 11.9 %, and 0.5% had mild,  
166 moderate, and severe anemia, respectively (Supplementary Table 1). Only 10,884 (8.4%) pregnant  
167 women had an Hb measurement before GA week 13, and 28,709 (18.1%) pregnant women had no  
168 Hb measurement during the entire pregnancy, although they attended ANC (Supplementary Table  
169 1). Having two Hb measurements during pregnancy was the most common scenario (n=67,425,  
170 51.9%).

171 The prevalence of anemia differed across the 12 administrative regions in Georgia and was lowest  
172 in Samtskhe-Javakheti (25.1%) and Racha (34.4%) and highest in Adjara (47.0%) and Kvemo  
173 Kartli (46.5%) (Fig. 2).

174 The proportion of women with no or no reliable Hb measurements during pregnancy also varied  
175 considerably across regions; it was highest in Samegrelo and Zemo Svaneti, where 33.3% of  
176 pregnant women had no registered Hb measurement and lowest in Samtskhe-Javakheti (7.1%) and  
177 Imereti (8.0%) (Supplementary Table 2). The number of women who did not attend ANC also  
178 varied by region; Mtskheta-Mtianeti and Kakheti had the highest proportions of non-attendance  
179 (6.6% and 6.1%, respectively) and Adjara, Imereti, and Samtskhe-Javakheti had the lowest  
180 proportions (2.6%) (Supplementary Table 3).

181 *Figure 2. Anemia prevalence in Georgian regions, 2019-2022*

182

183 Of the 105,811 included women with Hb measurement in their third trimester, 71.0% had no  
184 anemia, 20.9% had mild anemia, and 8.1% had moderate or severe anemia (Table 1). The third  
185 trimester prevalence of anemia varied by year and was highest in 2019 (25.9% and 11.5% for mild  
186 and moderate/severe anemia, respectively) and lowest in 2022 (17.3% and 5.9% for mild and  
187 moderate/severe anemia, respectively). The mean maternal age was around 28 years for all  
188 anemia groups. Most women lived in urban areas, had secondary education, attended between

189 four and eight ANC visits, were normal weight, multipara, had a singleton pregnancy, and delivered  
 190 vaginally. Notably, mild anemia was mostly diagnosed at GA week 35, and moderate/severe at GA  
 191 week 34. Women with anemia in the third trimester were more likely to have more than eight ANC  
 192 visits, have a BMI below 18.5 kg/m<sup>2</sup> at GA week <13, and be multiparous compared to women with  
 193 no anemia in the third trimester. Bleeding during pregnancy was rare in all pregnant women and  
 194 was almost equally distributed across all three anemia groups. Characteristics according to anemia  
 195 status for the total study sample (Supplementary Table 1) were similar to those of the subsample of  
 196 women with Hb measurement in the third trimester.

197 *Table 1. Maternal Baseline Characteristics by Anemia Status During Third Trimester of Pregnancy*

<b>Characteristics</b>	<b>No anemia &gt;110 g/L</b>	<b>Mild 100-109 g/L</b>	<b>Moderate &amp; Severe &lt;99 g/L</b>
n (row, %)	75,114 (71.0)	22,122 (20.9)	8,575 (8.1)
Year of delivery, n (row, %)			
2019	18,339 (62.6)	7,579 (25.9)	3,367 (11.5)
2020	21,185 (72.0)	5,911 (20.1)	2,324 (7.9)
2021	22,218 (74.8)	5,624 (18.9)	1,852 (6.3)
2022	13,372 (76.8)	3,008 (17.3)	1,032 (5.9)
Age, mean (SD)	28.3 (5.68)	28.1 (5.75)	27.8 (5.77)
Residency, n (%)			
Urban	55,531 (73.9)	16,495 (74.6)	6,325 (73.8)
Rural	19,578 (26.1)	5,625 (25.4)	2,250 (26.2)
Unknown	5 (0.01)	2 (0.01)	0 (0.0)
Education, n (%)			
Primary	4,470 (6.0)	1,501 (6.8)	731 (8.5)
Secondary	30,879 (41.1)	9,594 (43.4)	3,687 (43.0)
Higher	27,221 (36.2)	7,330 (33.1)	2,479 (28.9)
Unknown	12,521 (16.7)	3,697 (16.7)	1,678 (19.6)
ANC visits, n (%)			
< 4	1,676 (2.2)	556 (2.5)	321 (3.7)
4-8	55,742 (74.2)	15,980 (72.2)	6,037 (70.4)
>8	17,696 (23.6)	5,586 (25.3)	2,217 (25.9)
BMI, n (%) <sup>1</sup>			
<18.5	4,987 (6.8)	1,565 (7.3)	610 (7.5)
18.5-24.9	43,338 (59.4)	12,948 (60.7)	5,077 (62.1)
25-30	16,052 (22.0)	4,618 (21.7)	1,646 (20.2)
>30	8,594 (11.8)	2,194 (10.3)	839 (10.3)
Parity, n (%)			
Nullipara	31,606 (42.1)	8,130 (36.8)	2,913 (34.0)
Multipara	43,508 (57.9)	13,992 (63.2)	5,662 (66.0)
Plurality, n (%)			
Singleton	74,424 (99.1)	21,887 (99.0)	8,455 (98.6)
Multiple	690 (0.9)	235 (1.0)	120 (1.4)
GA at lowest Hb value, mean (SD)	35.5 (1.70)	34.9 (2.27)	34.7 (2.47)

Lowest recorded Hb value, mean (SD)	118 (0.83)	104 (0.31)	90 (1.00)
Bleeding during pregnancy, n (%)			
Yes	1,166 (1.6)	451 (2.0)	165 (1.9)
No	73,948 (98.4)	21,671 (98.0)	8,410 (98.1)
Mode of delivery, n (%)			
CS	30,202 (40.2)	9,031 (40.8)	3,656 (42.6)
Vaginal	44,912 (59.8)	13,091 (59.2)	4,919 (57.4)

198 <sup>1</sup> 3,343 observations are not having BMI measures

199 Among women with at least one Hb measurement in the third trimester, 558 were admitted to the  
 200 post-delivery ICU, and the proportions were relatively similar across the anemia groups (no  
 201 anemia:0.5%, mild and moderate/severe anemia:0.6%) (Table 3). Furthermore, 3,411 women  
 202 delivered preterm, and the proportion of preterm deliveries was similar in all exposure groups (3.2%  
 203 in the non-anemia, mild, and moderate/severe anemia groups). After adjustments for confounding  
 204 factors, women with mild or moderate/severe anemia experienced higher odds of post-delivery ICU  
 205 admission than the reference group (aOR, 1.19; 95% CI, 0.97–1.46 and aOR, 1.24; 95% CI, 0.93–  
 206 1.66, respectively), although the association was non-significant with a .05 threshold, and there was  
 207 no sufficient evidence for a linear trend ( $P$  for trend = .13). In contrast, we observed a linear inverse  
 208 association between anemia and preterm delivery (mild: aOR, 0.95; 95% CI 0.87-1.04; moderate  
 209 and severe: aOR, 0.93; 95% CI 0.82-1.06, respectively, and  $P$  for trend= .01).

210 *Table 2. Unadjusted and aORs and 95% CIs for the association between anemia during pregnancy*  
 211 *and post-delivery ICU admission and preterm delivery*

Outcome	Non anemia (reference group) n=75,114		Mild 100-109 g/L n=22,122			Moderate & Severe <99 g/L n=8,575			p-value for linear trend
	n (%)	OR/aOR	n (%)	OR (95%CI)	aOR (95%CI)	n (%)	OR (95%CI)	aOR (95%CI)	
Post-delivery ICU admission	377 (0.5)	1.0/1.0	129 (0.6)	1.16 (0.95-1.42)	1.19 (0.97-1.46)	52 (0.6)	1.21 (0.90-1.62)	1.24 (0.93-1.66)	0.13
Preterm delivery	2,436 (3.2)	1.0/1.0	699 (3.2)	0.97 (0.89-1.06)	0.95 (0.87-1.04)	276 (3.2)	0.99 (0.87-1.13)	0.93 (0.82-1.06)	0.01

212

## 213 Discussion

214 This is the first national birth registry-based study to describe the prevalence of anemia in pregnant  
215 women in Georgia and evaluate its association with selected adverse maternal outcomes.

216 According to Hb measurements in the GBR, 40.6% of pregnant women in Georgia who delivered  
217 between January 1, 2019, and August 31, 2022, had anemia at least once during their pregnancy.  
218 Adjara in Western Georgia had the highest prevalence of women with anemia (47.0%), whereas  
219 Samtskhe-Javakheti in the south had the lowest prevalence (25.1%). Our results suggest that the  
220 overall prevalence of anemia during pregnancy is slightly higher than the global estimate of anemia  
221 in pregnant women (36.5%) in 2019 provided by World Bank Health Nutrition and Population  
222 Statistics [33]. Moreover, the same source indicated that the prevalence in Georgia is higher than  
223 those of neighboring countries, Armenia (18.1%) and Azerbaijan (35%). According to the 2019  
224 WHO Global Health Observatory Data Repository, the prevalence of anemia in pregnant women in  
225 Georgia is higher than the average prevalence for upper-middle-income countries in Europe  
226 (24.5%) and substantially higher than those of high-income countries (17.2%) [34]. There is a  
227 considerable difference in the prevalence of anemia between the regions of Georgia. Accordingly,  
228 the presented prevalence for Adjara (47.0%), Kvemo Kartli (46.5%), Imereti (44.1%) and Guria  
229 (42.6%) are close to the anemia prevalence in low-income countries (42.6%) whereas the anemia  
230 prevalence in Samtskhe-Javakheti (25.1%) is closer to the prevalence in WHO European region  
231 (23.5%) [33, 34]. Specific dietary practices and differences in nutrition are possible explanations for  
232 the observed regional differences. For instance, in Western Georgia, red meat is less commonly  
233 consumed compared to the other parts of the country; this can partly explain the substantially  
234 higher prevalence of anemia in Adjara and Imereti than in Samtskhe-Javakheti.

235 The proportion of women with mild (28.3%), moderate (11.9%), and severe (0.5%) anemia in  
236 Georgia was consistent with pooled estimates from Canada and China [8, 9, 12, 18], and lower  
237 than that the reported values for some African and Asian countries, such as Somalia, India, and

238 Pakistan [10, 35]. The low prevalence of severe anemia suggests that implemented national public  
239 health measures for anemia prevention, such as free screening and treatment among pregnant  
240 women, are efficient. Women with anemia were also more likely to have more than eight ANC  
241 visits than women without anemia, indicating that women who have been screened and diagnosed  
242 with anemia receive more intense follow-up and treatment than others, which might have resulted  
243 in the low observed prevalence of severe anemia.

244 Another important finding of this study is that 18.1% of all pregnant women who visited the ANC  
245 had no reliable Hb measurement during their entire pregnancy, and this proportion varied  
246 considerably across the country (Supplementary Table2). This may impact statistics on the true  
247 prevalence of anemia in the country and in certain regions. According to the State Antenatal Care  
248 Guidelines, all pregnant women attending ANC should have at least one Hb measurement [27].  
249 Hence, the above proportion of women without Hb measurements indicates that despite state-  
250 supported ANC and free access to medication for the treatment of iron deficiency anemia during  
251 pregnancy (if detected before GA week 13), almost one-fifth of all pregnant women may not receive  
252 the care they require or if they do, it may not be registered in the GBR, although this registration is  
253 mandatory for ANC providers. These findings suggest that a major priority for Georgian  
254 decisionmakers should be to identify the reasons behind the lack of Hb measurements, resolve  
255 problems with the registration of implausible values, and follow up women with no Hb  
256 measurements to ensure equal access to high-quality ANC for all pregnant women across the  
257 country.

258 Consistent with previous reports, this registry-based study demonstrated an association between  
259 anemia during the third trimester and increased odds of admission to the post-delivery ICU [9, 35],  
260 although this was not statistically significant using a 5% threshold ( $P$  for trend = .13). Anemia in  
261 pregnancy is a well-known risk factor for post-partum hemorrhage [11], which leads to post-delivery  
262 ICU admission. Our results should be interpreted with caution but are notable since hemorrhage

263 has been identified as the leading direct cause of post-delivery ICU admission in Georgia,  
264 eventually leading to maternal death [25]. Timely and properly initiated preventive interventions are  
265 required during ANC to reduce the risk of maternal morbidity and mortality in Georgia, especially  
266 since the maternal mortality rate has increased since 2020 [23].

267 In contrast to previous studies [3, 8, 10, 35, 36], we found no increased odds for preterm delivery  
268 among mothers with anemia in the third trimester, and this is a good message for decisionmakers  
269 of the Georgian national healthcare. In fact, we observed an inverse linear trend, suggesting that  
270 women with anemia have lower odds of preterm delivery than women without anemia ( $P$  for trend  
271 =0.01). This seems contradictory because several other studies have reported an increased risk of  
272 preterm delivery [2, 4]. However, the risk seems to differ according to trimester and across studies;  
273 for example, a systematic review and meta-analysis from South Africa, published in 2022 highlights  
274 difficulties in clarifying the association between anemia and preterm delivery and in which direction  
275 the association might be [12]. Similarly, meta-analyses published in 2000 [37] and 2019 [7] reported  
276 a non-significant inverse relationship between anemia in late pregnancy and preterm delivery,  
277 which is in accordance with our results. One possible explanation for this difference could be that  
278 women in middle-income countries with a well-developed registration system receive intensive  
279 follow-up and treatment if they are diagnosed with anemia, while women in lower-income countries  
280 with limited capacities in the healthcare sector may not receive optimal follow-up and medical care  
281 due to a lack of resources or different screening approaches [8]. Our results show a higher  
282 frequency of ANC in pregnant women with a low Hb value. Thus, with special care and treatment,  
283 anemia-related preterm delivery is an avoidable adverse maternal outcome, and anemia could be  
284 effectively managed even during the third trimester of pregnancy.

285 The substantial differences in the regional prevalence of anemia in Georgia highlight the need for a  
286 customized and stronger public health response and policy implementation toward anemia as a  
287 significant public health challenge in Georgia. The proportions of pregnant women who do not

288 attend ANC and of those with no registered Hb values indicate the need for a coordinated strategy  
289 to ensure that women in Georgia have equal access and receive optimal care independent of their  
290 place of residence. Moreover, it is advisable to evaluate the registration structure of service-related  
291 information in the GBR. Nevertheless, focusing on increased, countrywide coverage of the state  
292 ANC program with all its features, better access to optimal ANC, and coordinated customized,  
293 multilevel responses against anemia are important steps toward mitigating the consequences of  
294 maternal anemia and equalizing regional disparities in anemia prevalence.

## 295 **Strength and limitations**

296 The strength of this study is the large number of women we included, which makes the study  
297 representative of pregnant women in Georgia. However, almost one-fifth of the women did not have  
298 a valid Hb measurement. Women who do not attend ANC may have a higher risk of anemia  
299 because they do not receive proper follow-up from medical personnel. The significant number of  
300 pregnant women not attending ANC may have affected the prevalence estimate in the present  
301 study. Consequently, there is a need to improve ANC operations to obtain reliable estimates of the  
302 prevalence of anemia in pregnant women in Georgia. Based on the GBR data, most women  
303 underwent more than one Hb measurement. However, we classified the women according to the  
304 lowest registered Hb value and did not consider whether the women were treated or whether the  
305 Hb level of those who were treated normalized. This is a limitation of the study. In addition, anemia  
306 was identified using measured Hb values, and we could not specify the type of anemia. Moreover,  
307 despite controlling for many covariates in the multivariate-adjusted regression analyses,  
308 measurement errors could have resulted in residual confounding, and we had no information about  
309 several important factors, especially comorbidities such as chronic kidney disease, infections, and  
310 cancer, which could have influenced the results.

311 Despite these limitations, this study provides important insight into the prevalence and potential  
312 consequences of anemia in pregnant women in Georgia.

## 313 **Conclusion**

314 Approximately one-third of pregnant women in Georgia experience anemia at any time during  
315 pregnancy, but severe anemia is rare. One-fifth of the women who attended ANC did not have any  
316 valid Hb measurement, which is surprising and worrisome since Hb measurements are covered by  
317 the state of Georgia. There were large regional differences in the prevalence of anemia, which  
318 warrant further investigation. To accelerate progress toward sustainable development goals and  
319 decrease the public health burden of anemia in Georgia, early identification and adequate  
320 management of anemia during pregnancy are crucial.

321

## 322 **Acknowledgments**

323 The authors would like to acknowledge the assistance of the Institute of Hematology and  
324 Transfuziology in providing important insights regarding the study design.

325 Moreover, the authors would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

326 The publication charges for this article have been funded by a grant from the publication fund of UiT

327 The Arctic University of Norway.



## 328 References

- 329 1. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and  
330 assessment of severity. WHO/NMH/NHD/MNM/111. WHO; 2023. p. 6. Available from:  
331 [https://apps.who.int/iris/bitstream/handle/10665/85839/WHO\\_NMH\\_NHD\\_MNM\\_11.1\\_eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf)
- 332 2. Shand AW, Kidson-Gerber GL. Anaemia in pregnancy: a major global health problem.  
333 Lancet. 2023;401: 1550-1551. Epub 20230421. doi: [10.1016/S0140-6736\(23\)00396-3](https://doi.org/10.1016/S0140-6736(23)00396-3).
- 334 3. Frayne J, Pinchon D. Anaemia in pregnancy. Aust J Gen Pract. 2019;48: 125-129. doi:  
335 [10.31128/AJGP-08-18-4664](https://doi.org/10.31128/AJGP-08-18-4664).
- 336 4. Benson AE, Shatzel JJ, Ryan KS, Hedges MA, Martens K, Aslan JE, et al. The incidence,  
337 complications, and treatment of iron deficiency in pregnancy. Eur J Haematol. 2022;109: 633-642.  
338 Epub 20221004. doi: [10.1111/ejh.13870](https://doi.org/10.1111/ejh.13870).
- 339 5. Editorial. Lancet Haematol. 2022. [cited 2022]. Available from:  
340 [https://doi.org/10.1016/S2352-3026\(22\)00325-8](https://doi.org/10.1016/S2352-3026(22)00325-8)
- 341 6. Maged AM, Elsherief A, Hassan H, Salaheldin D, Omran KA, Almohamady M, et al..  
342 Maternal, fetal, and neonatal outcomes among different types of hypertensive disorders associating  
343 pregnancy needing intensive care management. J Matern Fetal Neonatal Med. 2020;33: 314–321.  
344 doi: [10.1080/14767058.2018.1491030](https://doi.org/10.1080/14767058.2018.1491030).
- 345 7. Rahmati S, Azami M, Badfar G, Parizad N, Sayehmiri K. The relationship between maternal  
346 anemia during pregnancy with preterm birth: a systematic review and meta-analysis. J Matern Fetal  
347 Neonatal Med. 2020;33: 2679-2689. Epub 20190409. doi: [10.1080/14767058.2018.1555811](https://doi.org/10.1080/14767058.2018.1555811).
- 348 8. Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and  
349 mortality associated with anemia in pregnancy. Obstet Gynecol. 2019;134: 1234-1244. doi:  
350 [10.1097/AOG.0000000000003557](https://doi.org/10.1097/AOG.0000000000003557).
- 351 9. Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, et al. Severity of anemia during pregnancy  
352 and adverse maternal and fetal outcomes. JAMA Netw Open. 2022;5: e2147046. doi:  
353 [10.1001/jamanetworkopen.2021.47046](https://doi.org/10.1001/jamanetworkopen.2021.47046).
- 354 10. Barut A, Mohamad DO. The association of maternal anaemia with adverse maternal and  
355 foetal outcomes in Somali women: a prospective study. BMC Womens Health. 2023;23: 193. doi:  
356 [10.1186/s12905-023-02382-4](https://doi.org/10.1186/s12905-023-02382-4).
- 357 11. Mansukhani R, Shakur-Still H, Chaudhri R, Bello F, Muganyizi P, Kayani A, et al. Maternal  
358 anaemia and the risk of postpartum haemorrhage: a cohort analysis of data from the WOMAN-2  
359 trial. Lancet Glob Health. 2023;11: e1249–e1259-e59. doi: [10.1016/S2214-109X\(23\)00245-0](https://doi.org/10.1016/S2214-109X(23)00245-0).
- 360 12. Dorsamy V, Bagwandeem C, Moodley J. The prevalence, risk factors and outcomes of  
361 anaemia in South African pregnant women: a systematic review and meta-analysis. Syst Rev.  
362 2022;11: 16. doi: [10.1186/s13643-022-01884-w](https://doi.org/10.1186/s13643-022-01884-w).
- 363 13. Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV, Local Burden of Disease Anaemia  
364 Collaborators, Kassebaum NJ, Hay SI. Anemia prevalence in women of reproductive age in low-  
365 and middle-income countries between 2000 and 2018. Nat Med. 2021;27: 1761-1782. doi:  
366 [10.1038/s41591-021-01498-0](https://doi.org/10.1038/s41591-021-01498-0).
- 367 14. Karami M, Chaleshgar M, Salari N, Akbari H, Mohammadi M. Global prevalence of anemia  
368 in pregnant women: A comprehensive systematic review and meta-analysis. Matern Child Health J.  
369 2022;26: 1473-1487. doi: [10.1007/s10995-022-03450-1](https://doi.org/10.1007/s10995-022-03450-1), PubMed PMID: [35608810](https://pubmed.ncbi.nlm.nih.gov/35608810/).
- 370 15. World Health Organization. Maternal, infant and young child nutrition. Comprehensive  
371 implementation plan on maternal, infant and young child nutrition: biennial report; 2021. Available  
372 from: [https://apps.who.int/gb/ebwha/pdf\\_files/EB150/B150\\_23-en.pdf](https://apps.who.int/gb/ebwha/pdf_files/EB150/B150_23-en.pdf)
- 373 16. United Nations. Global indicator framework for the Sustainable Development Goals and  
374 targets of the 2030 Agenda for Sustainable Development; 2012. Available from:  
375 [https://unstats.un.org/sdgs/indicators/Global%20Indicator%20Framework%20after%202020%20rev](https://unstats.un.org/sdgs/indicators/Global%20Indicator%20Framework%20after%202020%20review_Eng.pdf)  
376 [iew\\_Eng.pdf](https://unstats.un.org/sdgs/indicators/Global%20Indicator%20Framework%20after%202020%20review_Eng.pdf)

- 377 17. World Health Organization. WHO calls for accelerated action to reduce anaemia; 2023.  
378 Available from: [https://www.who.int/news/item/12-05-2023-who-calls-for-accelerated-action-to-](https://www.who.int/news/item/12-05-2023-who-calls-for-accelerated-action-to-reduce-anaemia)  
379 [reduce-anaemia](https://www.who.int/news/item/12-05-2023-who-calls-for-accelerated-action-to-reduce-anaemia)
- 380 18. Stevens GA, Paciorek CJ, Flores-Urrutia MC, Borghi E, Namaste S, Wirth JP, et al.  
381 National, regional, and global estimates of anaemia by severity in women and children for 2000-19:  
382 a pooled analysis of population-representative data. *Lancet Glob Health*. 2022;10: e627-e639. doi:  
383 [10.1016/S2214-109X\(22\)00084-5](https://doi.org/10.1016/S2214-109X(22)00084-5).
- 384 19. Wiesenack C, Meybohm P, Neef V, Kranke P. Current concepts in preoperative anemia  
385 management in obstetrics. *Curr Opin Anaesthesiol*. 2023;36: 255-262. doi:  
386 [10.1097/ACO.0000000000001252](https://doi.org/10.1097/ACO.0000000000001252).
- 387 20. National Statistics Office of Georgia. Population and demography. Georgia: GeoStat; 2023.  
388 Available from: <https://www.geostat.ge/en/modules/categories/316/population-and-demography>
- 389 21. National Center for Disease Control and Public Health of Georgia. Strengthening  
390 surveillance of micronutrient deficiency in Georgia. Atlanta: Centers for Disease Control and  
391 Prevention (CDC); 2019. Available from: [https://test.ncdc.ge/Handlers/GetFile.ashx?ID=c1d01e1d-](https://test.ncdc.ge/Handlers/GetFile.ashx?ID=c1d01e1d-0a11-4823-bd48-d3dff0a8723f)  
392 [0a11-4823-bd48-d3dff0a8723f](https://test.ncdc.ge/Handlers/GetFile.ashx?ID=c1d01e1d-0a11-4823-bd48-d3dff0a8723f)
- 393 22. World Health Organization. WHO recommendations on antenatal care for a positive  
394 pregnancy experience. Summary. 2018. Available from:  
395 <https://apps.who.int/iris/bitstream/handle/10665/259947/WHO-RHR-18.02-eng.pdf>
- 396 23. National Center for Disease Control and Public Health of Georgia. Health care. Statistical  
397 yearbook. NCDC, 2022. Available from: [https://ncdc.ge/#/pages/file/b3956fe5-2a48-4fc1-9a5a-](https://ncdc.ge/#/pages/file/b3956fe5-2a48-4fc1-9a5a-37d13c6d397f)  
398 [37d13c6d397f](https://ncdc.ge/#/pages/file/b3956fe5-2a48-4fc1-9a5a-37d13c6d397f)
- 399 24. Anda EE, Nedberg IH, Rylander C, Gamkrelidze A, Turdziladze A, Skjeldestad FE, et al.  
400 Implementing a birth registry in a developing country - experiences from Georgia. *Tidsskr Nor*  
401 *Laegeforen*. 2017;138. Epub 20171220. doi: [10.4045/tidsskr.17.0553](https://doi.org/10.4045/tidsskr.17.0553).
- 402 25. Skhvitaridze N, Anda EE, Brenn T, Kintraia N, Gamkrelidze A. Scoping maternal care  
403 through the lens of maternal deaths: A retrospective analysis of maternal mortality in Georgia. *Sex*  
404 *Reprod Healthc*. 2020;26: 100560. doi: [10.1016/j.srhc.2020.100560](https://doi.org/10.1016/j.srhc.2020.100560).
- 405 26. National Center for Disease Control and Public Health of Georgia. Three years report on  
406 pregnancy and newborns health surveillance electronic registry (Birth Registry). Georgia: NCDC;  
407 2021. Available from: [https://test.ncdc.ge/Handlers/GetFile.ashx?ID=212d3669-f55b-4b41-ae44-](https://test.ncdc.ge/Handlers/GetFile.ashx?ID=212d3669-f55b-4b41-ae44-88cf5cf43e5a)  
408 [88cf5cf43e5a](https://test.ncdc.ge/Handlers/GetFile.ashx?ID=212d3669-f55b-4b41-ae44-88cf5cf43e5a)
- 409 27. Ministry of internally displaced persons from the occupied territories, health and social  
410 affairs. Antenatal care, Guideline. Politics DoH; 2017. Available from:  
411 <https://www.moh.gov.ge/uploads/guidelines/2018/01/30/27c73e076a8aa47c01ccca4200f1e075.pdf>
- 412 28. National Institute for Health and Care Excellence. Antenatal care; 2021. Available from:  
413 <https://www.nice.org.uk/guidance/ng201>
- 414 29. Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F, et al.  
415 Global, regional, and national trends in haemoglobin concentration and prevalence of total and  
416 severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic  
417 analysis of population-representative data. *Lancet Glob Health*. 2013;1: e16-e25. Epub 20130625.  
418 doi: [10.1016/S2214-109X\(13\)70001-9](https://doi.org/10.1016/S2214-109X(13)70001-9).
- 419 30. International statistical classification of diseases and related health problems. 10<sup>th</sup> revision.  
420 2<sup>nd</sup> ed.; 2004. (p. ICD-10). Available from: <https://apps.who.int/iris/handle/10665/246208>
- 421 31. World Health Organization. A healthy lifestyle – WHO recommendations; 2010. Available  
422 from: [https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-](https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations)  
423 [recommendations](https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations)
- 424 32. Ministry of internally displaced persons from the occupied territories, health and social  
425 affairs. About the rules of production and delivery of medical statistics. Ministry of Health; 2019.  
426 Available from: <https://matsne.gov.ge/en/document/view/4509878?publication=>
- 427 33. World Bank. Prevalence of anaemia among pregnant women (%). WB; 2023. Available  
428 from: <https://databank.worldbank.org/reports.aspx?source=2&series=SH.PRG.ANEM&country=>

429 34. World Health Organization. Anaemia in pregnant women Estimates by World Bank income  
430 group; 2023. Available from: [https://apps.who.int/gho/data/view.main-](https://apps.who.int/gho/data/view.main-eu.ANAEMIAWOMENPWWBINCOMEGRUPOV?lang=en)  
431 [eu.ANAEMIAWOMENPWWBINCOMEGRUPOV?lang=en](https://apps.who.int/gho/data/view.main-eu.ANAEMIAWOMENPWWBINCOMEGRUPOV?lang=en)  
432 35. Parks S, Hoffman MK, Goudar SS, Patel A, Saleem S, Ali SA, et al. Maternal anaemia and  
433 maternal, fetal, and neonatal outcomes in a prospective cohort study in India and Pakistan. BJOG.  
434 2019;126: 737-743. Epub 20190124. doi: [10.1111/1471-0528.15585](https://doi.org/10.1111/1471-0528.15585).  
435 36. Harrison RK, Lauhon SR, Colvin ZA, McIntosh JJ. Maternal anemia and severe maternal  
436 morbidity in a US cohort. Am J Obstet Gynecol MFM. 2021;3: 100395. Epub 20210513. doi:  
437 [10.1016/j.ajogmf.2021.100395](https://doi.org/10.1016/j.ajogmf.2021.100395).  
438 37. Xiong X, Buekens P, Alexander S, Demianczuk N, Wollast E. Anemia during pregnancy and  
439 birth outcome: a meta-analysis. Am J Perinatol. 2000;17: 137-146. doi: [10.1055/s-2000-9508](https://doi.org/10.1055/s-2000-9508).  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465

466 **Author contribution**

467 All authors contributed to the methodology, analysis, writing, and editing of the manuscript. All  
468 authors approved the final version of the manuscript and agreed to be responsible for all provided  
469 information. CR, TM, TB, EA and AG supervised the study. NS, CR, and TM summarized the  
470 national datasets and contributed to data collection and curation. NS drafted the manuscript and  
471 amended it according to feedback from all authors.

472 **Conflict of interest**

473 The authors declare that they have no conflict of interest.

474 **Consent for publication**

475 Not applicable.

476 **Financial disclosure**

477 This study has not received any funding.

478 **Availability of data and materials**

479 According to Georgian legislation, data from central health registries can be used for research  
480 purposes as long as personal data is not shared. Data collected for this study are not publicly  
481 available because they contain personalized and potentially identifying information. Proper ethical  
482 and legal approvals are required for access before requesting the data, and only  
483 anonymous/pseudonymized data can be shared. Researchers can contact the National Center for  
484 Disease Control and Public Health in Georgia ([ncdc@ncdc.ge](mailto:ncdc@ncdc.ge)) or the corresponding author  
485 ([natia.skhvitaridze@uit.no](mailto:natia.skhvitaridze@uit.no)) for assistance on how to apply for access to data from registry.

486

487

488

489

## 490 **Supporting information**

491 **Figure 1.**

492 **Figure 2.**

493 **S1 File.**

494 **S2 File.**

495 **S1 Table.**

496 **S2 Table.**

497 **S3 Table.**

Figure 1. Flow chart of the study sample






Figure 1

Figure 2. Anemia prevalence in Georgian regions, 2019-2022

Prevalence range



Created with Datawrapper

Figure 2